¹⁶¹Tb-PSMA-617

¹⁶¹Tb-PSMA-617 is a terbium-161-labeled radioligand therapy developed by Torpedo Pharmaceuticals for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The drug utilizes the PSMA-617 ligand, which binds with high affinity to the prostate-specific membrane antigen (PSMA) expressed on the surface of prostate cancer cells. The ligand is conjugated to terbium-161 (¹⁶¹Tb), a radioisotope that emits beta particles, Auger electrons, and conversion electrons. This combination of emissions provides a higher linear energy transfer (LET) and a higher absorbed dose to small tumor clusters and single cells compared to traditional beta-emitters like lutetium-177. The short-range Auger electrons are particularly effective at inducing lethal DNA damage when the radioligand is internalized, potentially overcoming resistance mechanisms in advanced prostate cancer. It is currently undergoing Phase 1 clinical evaluation.

Other names

161Tb-PSMA-617terbium-161-PSMA-617terbium161-PSMA-617terbium 161-PSMA-617Tb-161-PSMA-617Tb161-PSMA-617Tb 161-PSMA-617